Table 2. Treatment and clinical characteristics of subjects (N = 14).

DLBCL, diffuse large B cell lymphoma; NED, no evidence of disease; NR, no response. MRD tested by deep sequencing analysis as described in Materials and Methods.

IDTotal T
cells
infused
(× 108)
Total CTL019
cells infused
(× 108)
Peak CTL019
expansion
(% of CD3+ cells)
Best overall
response
Last follow-up or
progression
(months)
Comments, current status
015011.3N/ACR53MRD-negative; progression-free
023.00.142N/ACR52MRD-negative; progression-free
0325.55.86N/APR5Progression, 5 months; died of disease, 27 months
0510.03.9214.1PR13Progression, 13 months; alive with disease, 36 months
063.00.6460.2NR1Died of disease, 8 months
071.70.1720.3NR1Died of complications from bone marrow transplant, 9 months
095.01.7081.9CR21MRD-negative; progression-free, 21 months; died of infection
1030.05.6134.3CR28Bulky adenopathy (11 cm); MRD-negative;
progression-free
125.01.1818.3PR6Bulky adenopathy (9 cm); died of
pulmonary embolus
1418.01.56<0.1NR7Alive with disease, 26 months
174.21.031.6NR10Alive with disease, 18 months
1850.02.770.2NR4Alive with disease, 17 months
225.00.86434.9PR10Bulky adenopathy (9 cm); progressed 10 months with
transformed CD19-dim DLBCL; died of disease at 10 months
2520.02.712.6NR3Alive with disease, 16 months

*CTL019 refers to transduced, CAR-modified T cells.

†Subjects 01, 02, and 03 were not evaluated for early expansion by flow cytometry because an antibody to detect CTL019 cells was not available at the time of their treatment.